This AI screening tool for diabetic retinopathy makes a decision, not a recommendation - MedCity News

Artificial intelligence is a healthcare and technology buzzword right now, but IDx Founder and President Michael Abràmoff is not a Johnny-come-lately to this phenomenon. His journey and that of the company's lead product began over two decades ago in the Netherlands. The product, IDx-DR, is an AI-based diagnostic system meant to be used as a standalone screening tool for diabetic retinopathy. Last week, the company announced that it submitted an application with the FDA, which the agency accepted with a "breakthrough device" designation. In other words, based on its ability to address an unmet medical need, FDA will provide a faster review.